


IASOflu® case report from Medical University Hospital Innsbruck, Austria

A 76 year old castration resistant prostate cancer patient with history of radiation therapy of the prostate, presented with multiple bone metastases, as demonstrated on ¹⁸F-NaF (IASOflu®) PET (Fig. a).

A targeted therapy with six cycles of Rd-223 (Xofigo®) with a total activity of 22.34 MBq was performed. In a follow-up, IASOflu® PET, performed for assessment of therapy response after completion of the last cycle, showed a very good partial metabolic remission (Fig. b). The majority of the initially highly metabolic active bone metastases showed a markedly decrease of metabolic activity, as presented in a metastasis of the thoracic spine (Fig. c: lesion before and Fig. d: lesion after therapy).

This example demonstrates the valuable clinical contribution of IASOflu® PET in therapy response evaluation of patients with skeletal metastases.



*This case was kindly provided by **Unif. Prof. Irene Virgolini and Priv .Doz. Dr. Christian Uprimny** from the Department of Nuclear Medicine, Medical University Innsbruck, Austria.*